BIO has a ‘frank conversation’ about systemic racism in biotech
Protests around the world have cast a light on the systemic racism at play in health care, education, housing, and policing. Biotech is no exception. And BIO, the group behind the sector’s largest annual conference, didn’t let the moment pass without what organization CEO Michelle McMurry-Heath billed as a “frank conversation” about racism in the industry.
Tony Coles, CEO of Cerevel Therapeutics and a panelist in the discussion, likened racism to “a mutation” in the DNA of society. Legislative efforts like the Civil Rights Act were designed to be “targeted therapies” that would root it out, Coles said, but “what we really needed to do was CRISPR that mutation right out of our social DNA.”
The hour-long discussion, added at the last minute to BIO’s schedule, touched on how executives are addressing the death of George Floyd within their companies, what it means to be a Black CEO in biotech, and the importance of having uncomfortable conversations about race with friends and colleagues.
Read more.
Tony Coles, CEO of Cerevel Therapeutics and a panelist in the discussion, likened racism to “a mutation” in the DNA of society. Legislative efforts like the Civil Rights Act were designed to be “targeted therapies” that would root it out, Coles said, but “what we really needed to do was CRISPR that mutation right out of our social DNA.”
The hour-long discussion, added at the last minute to BIO’s schedule, touched on how executives are addressing the death of George Floyd within their companies, what it means to be a Black CEO in biotech, and the importance of having uncomfortable conversations about race with friends and colleagues.
Read more.
.png)
No hay comentarios:
Publicar un comentario